Home End-Stage Renal Disease

U.S. CPT® Code Granted for KidneyIntelX™

Renalytix AI plc is a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical Association (AMA) has granted a CPT® Proprietary Laboratory Analyses (PLA) Code for its lead product, KidneyIntelX™. The new code, 0105U, has been approved and published by the AMA CPT Editorial Panel, and is scheduled to become effective on October 1, 2019.

A payment rate for the new code will be established for Medicare patients through the 2019 Clinical Lab Fee Schedule (CLFS) Annual Public Meeting process. Renayltix AI will shortly provide comments and a recommendation on the appropriate basis for establishing a national Medicare price for this new CPT code expected to be effective January 1, 2020.

“This is an important step as we prepare for KidneyIntelX’s scaled roll-out in the United States,” said Michael J. Donovan, Ph.D., MD, Chief Medical Officer, RenalytixAI. “A CPT Code is instrumental in obtaining insurance coverage and reimbursement, and will increase access to KidneyIntelX testing results for patients with chronic kidney disease.”

The CPT terminology is the most widely accepted medical nomenclature used across the United States to report medical, surgical, radiology, laboratory, anesthesiology, genomic sequencing, evaluation and management services under public and private health insurance programs.  Recently added to the CPT Code set, PLA Codes are alpha-numeric CPT codes with a corresponding descriptor for labs or manufacturers that want to identify their test more specifically.

KidneyIntelX is designed to improve identification and clinical management of patients with Type 2 diabetes with fast-progressing kidney disease in an effort to curtail the estimated $114 billion annual cost1 of chronic and end-stage kidney disease to the United States healthcare system. KidneyIntelX uses machine learning algorithms to assess a combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, and features from a patient’s electronic health record.

In a recent study published April 1, 2019, and publicly announced by RenalytixAI on the same date, algorithms used at the core of KidneyIntelX significantly increased the ability to positively predict which patients went on to experience rapid kidney function decline (RKFD). For this group of patients experiencing RKFD and at significant risk of progressing to end-stage kidney disease and dialysis, there are several clinical management strategies and proven therapeutic options available. One of the greatest drivers of health care cost today is RKFD patients who are not diagnosed in time and face unplanned kidney failure through emergency room ‘crash’ dialysis.


1United States Renal Data System – https://www.usrds.org/adrhighlights.aspx.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version